CD22 and acute lymphoblastic leukemia: Recently, in pediatric patients (n = 25) with multiple R/R CD22+ ALL, functional properties of InO were confirmed in a phase 1 clinical trial (ITCC-059 study or EUDRA-CT 2016-000227-71).